Skip to content
Clinical Trials – home

Gesundheitsverbund Landkreis Konstanz gGmbH

Research site

Germany Virchowstrasse 10, 78224 Singen (Hohentwiel), Germany

  • 2 trials recruiting
  • Type 2 diabetes mellitus · Arteriosclerosis · Atrial fibrillation
  • Adult patients

About Specializations

Gesundheitsverbund Landkreis Konstanz gGmbH in Singen (Hohentwiel), Germany specialises in clinical trials of conditions such as Type 2 diabetes mellitus, Arteriosclerosis, Atrial fibrillation, Cardiovascular disorder, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Gesundheitsverbund Landkreis Konstanz gGmbH, clinical research in cardiovascular diseases focuses on reducing major heart and blood vessel complications, improving stroke prevention, and strengthening lipid management for people at elevated risk.

  • Adults at high risk of cardiovascular events
  • Atherosclerotic cardiovascular disease
  • Atrial fibrillation with prevention of stroke or systemic embolism
  • Hypercholesterolemia and elevated LDL cholesterol
  • Testing new therapies and comparing treatment effectiveness for cardiovascular protection

These studies include approaches aimed at lowering cardiovascular risk, improving long-term outcomes, and evaluating safer or more effective ways to manage heart disease and related complications.

Nutritional and Metabolic Diseases

The site also supports trials in nutritional and metabolic diseases, especially type 2 diabetes, obesity, and overweight, with a strong emphasis on better blood sugar control and broader cardiometabolic health.

  • Type 2 diabetes
  • Obesity and overweight
  • Improving glycaemic control in real-world care
  • Testing new glucose-lowering and cardiometabolic treatment strategies
  • Studying patients with combined diabetes, blood pressure, and cardiovascular risk

Research here is designed to assess whether newer treatment options can help people achieve better metabolic control while also supporting long-term cardiovascular health.

Neoplasms

In the area of neoplasms, the clinic is involved in studies for renal cell carcinoma and colon cancer, with research centered on improving cancer treatment effectiveness and disease-free survival.

  • Renal cell carcinoma
  • Colon cancer
  • Evaluating new combinations for cancer treatment
  • Comparing treatment strategies before and after surgery
  • Supporting better long-term cancer outcomes

These oncology trials explore whether new therapeutic approaches can improve how well patients respond to treatment and reduce the chance of cancer returning.

Digestive System Diseases

Clinical trial activity in digestive system diseases is represented by studies in colon cancer, where the focus is on refining treatment planning around surgery and improving the chance of durable disease control.

  • Colon cancer staged by imaging and surgical planning
  • Assessing preoperative and postoperative treatment approaches
  • Improving cancer-free survival after treatment
  • Comparing strategies to guide more effective care
  • Research at the I. Medizinische Klinik am Hegau-Bodensee-Klinikum

These studies aim to determine the most effective way to combine surgery and systemic therapy for patients with resectable disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Virchowstrasse 1078224 Singen (Hohentwiel)Germany
Recruiting now
2 trials
Conditions studied
15

More sites in Singen (Hohentwiel)Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

9 clinical trials

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Type 2 diabetes mellitus

Not yet recruiting

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin degludec
  • Sponsor:Novo Nordisk A/S

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Hypercholesterolaemia

Not recruiting

Study on Inclisiran and Rosuvastatin for Lowering Cholesterol in Patients with High Cholesterol Levels

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus+3

Not recruiting

Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Eli Lilly & Co.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.